Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Peter M. Hecht sold 113,405 shares of Ironwood Pharmaceuticals stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $15.12, for a total value of $1,714,683.60. Following the sale, the chief executive officer now directly owns 4,696,917 shares of the company’s stock, valued at approximately $71,017,385.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) opened at $15.49 on Monday. Ironwood Pharmaceuticals, Inc. has a twelve month low of $13.43 and a twelve month high of $19.94. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The company had revenue of $86.80 million for the quarter, compared to the consensus estimate of $73.59 million. During the same quarter in the previous year, the business earned ($0.18) EPS. Ironwood Pharmaceuticals’s revenue was up 31.3% compared to the same quarter last year. equities research analysts predict that Ironwood Pharmaceuticals, Inc. will post -1.12 earnings per share for the current year.
Several research firms have recently commented on IRWD. Credit Suisse Group began coverage on Ironwood Pharmaceuticals in a report on Monday, November 27th. They issued a “buy” rating and a $19.00 price objective on the stock. ValuEngine downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Mizuho downgraded Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $20.00 to $16.00 in a report on Wednesday, December 6th. BidaskClub upgraded Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Finally, Cowen set a $20.00 price objective on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 21st. Nine research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Ironwood Pharmaceuticals has an average rating of “Hold” and an average price target of $17.88.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/12/11/ironwood-pharmaceuticals-inc-irwd-ceo-sells-1714683-60-in-stock.html.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.